Cytonics is a biotechnology research and development company that specializes in developing diagnostics and therapeutics for osteoarthritis. Our flagship product was the Fibronectin-Aggrecan Complex Test (“FACT™”), which can detect cartilage damage due to osteoarthritis from samples of patients’ joint fluid. We licensed FACT™ to Synthes (acquired by Johnson & Johnson) in 2011, and it has been used by hundreds of physicians to diagnose and direct patients’ course of treatment.
Discovery of FAC as a biomarker for osteoarthritis led to the identification of a naturally-occurring blood protein, Alpha-2 Macroglobulin (A2M), which protects cartilage from degradation and can alleviate joint pain. We developed an autologous therapy (“APIC™”) based upon the function of A2M, which has sold directly to physicians by a national medical device distributor since 2015. Over 6,000 patients, ranging from the elderly to young athletes, have been treated to date. We are developing new A2M-based therapies with the goal of out-licensing to strategic partners at critical clinical value inflection points. Cytonics’ mission is to rid the world of the pain, suffering, and reduced quality of life caused by osteoarthritis. Supported by hundreds of physicians nationwide, we are a leader in the field of regenerative medicine and are positioned to disrupt the space with our innovative biologic therapies for osteoarthritis.
Our mission is to rid the world of the pain, suffering, and reduced quality of life caused by osteoarthritis.
“The individuals above were not compensated in exchange for their testimonials. In addition, their testimonials should not be construed as and/or considered investment advice.”
The company has developed relationships with researchers and clinicians at leading institutions around the country including Stanford University, University of Pittsburgh, Thomas Jefferson University, University of Michigan, NYU Hospital For Joint Diseases, and Beaumont Health System. Cytonics also has relationships with local institutions including The Scripps Research Institute, Florida Atlantic University, and Palm Beach State College. The company has sponsored research at Stanford University to study the use of FACT™ for patients with radiculopathic back pain, and at the University of Pittsburgh to investigate the effect of APIC™ on preventing spinal disc degeneration.
Be part of the relief for OA
Cytonics has received over $15M in funding to-date, including $1.8M in grants from the National Institute of Health and a $4M investment from Synthes (a Johnson and Johnson company). We are seeking to raise $1M by conducting a public offering under Regulation CF. Proceeds will be used to advance our lead drug candidate, Cyt-108, into FDA clinical trials and fund ongoing business operations.
Cytonics Corporation is offering securities under Regulation CF and Rule 506(c) of Regulation D through SI Securities, LLC (“SI Securities”). The Company has filed a Form C with the Securities and Exchange Commission in connection with its offering, a copy of which may be obtained at: https://seedinvest.com/cytonics